Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chabiotech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩575.97B | -40.8x | -0.84 | ₩10,540 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GC Cell | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩323.83B | -3.7x | 0 | ₩21,550 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Labgenomics | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩193.77B | -10.1x | 0.02 | ₩2,590 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dreamcis | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩78.42B | 12.9x | 0.22 | ₩3,270 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT CRO | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩60.66B | ₩4,675 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Biotoxtech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩48.26B | -6.1x | 0.19 | ₩3,090 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
U2Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩36.12B | ₩3,170 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
SLS Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩26.89B | ₩1,969 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |